Amarin (AMRN) Competitors

AbCellera Biologics (NASDAQ:ABCL) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Do analysts recommend ABCL or AMRN?

AbCellera Biologics currently has a consensus price target of $8.00, suggesting a potential upside of 164.03%. Given AbCellera Biologics' higher possible upside, research analysts clearly believe AbCellera Biologics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Amarin	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of ABCL or AMRN?

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 28.0% of AbCellera Biologics shares are held by insiders. Comparatively, 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer ABCL or AMRN?

Amarin received 790 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.06% of users gave AbCellera Biologics an outperform vote while only 73.78% of users gave Amarin an outperform vote.

Company	Underperform	Outperform
AbCellera Biologics	Outperform Votes 54 76.06%	Underperform Votes 17 23.94%
Amarin	Outperform Votes 844 73.78%	Underperform Votes 300 26.22%

Does the media favor ABCL or AMRN?

In the previous week, AbCellera Biologics had 7 more articles in the media than Amarin. MarketBeat recorded 10 mentions for AbCellera Biologics and 3 mentions for Amarin. AbCellera Biologics' average media sentiment score of 0.58 beat Amarin's score of -0.28 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ABCL or AMRN more profitable?

Amarin has a net margin of -16.33% compared to AbCellera Biologics' net margin of -533.32%. Amarin's return on equity of -7.22% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-533.32%	-15.73%	-12.22%
Amarin	-16.33%	-7.22%	-4.96%

Which has more risk & volatility, ABCL or AMRN?

AbCellera Biologics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Amarin has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Which has higher valuation and earnings, ABCL or AMRN?

Amarin has higher revenue and earnings than AbCellera Biologics. Amarin is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$38.03M	23.53	-$146.40M	-$0.61	-4.97
Amarin	$241.02M	1.00	-$59.11M	-$0.09	-6.55

Summary

AbCellera Biologics and Amarin tied by winning 9 of the 18 factors compared between the two stocks.